Capital International Sarl Bio N Tech Se Transaction History

Capital International Sarl

  • $3.71 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$80.36 - $102.87 $152,362 - $195,041
1,896 Added 7.88%
25,954 $2.09 Million
Q1 2024

May 14, 2024
BUY
$88.96 - $112.35 $27,577 - $34,828
310 Added 1.31%
24,058 $2.22 Million
Q4 2023

Feb 13, 2024
BUY
$90.91 - $112.75 $130,637 - $162,021
1,437 Added 6.44%
23,748 $2.51 Million
Q3 2023

Nov 13, 2023
BUY
$98.5 - $125.08 $260,532 - $330,836
2,645 Added 13.45%
22,311 $2.42 Million
Q2 2023

Aug 11, 2023
BUY
$102.58 - $129.66 $387,342 - $489,596
3,776 Added 23.76%
19,666 $2.12 Million
Q1 2023

May 15, 2023
BUY
$122.57 - $153.67 $309,734 - $388,324
2,527 Added 18.91%
15,890 $1.98 Million
Q4 2022

Feb 14, 2023
BUY
$118.43 - $186.05 $291,337 - $457,683
2,460 Added 22.56%
13,363 $2.01 Million
Q3 2022

Nov 14, 2022
BUY
$127.65 - $183.11 $1.39 Million - $2 Million
10,903 New
10,903 $1.47 Million
Q1 2022

May 16, 2022
SELL
$126.25 - $231.85 $718,110 - $1.32 Million
-5,688 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$216.64 - $362.52 $990,478 - $1.66 Million
4,572 Added 409.68%
5,688 $1.47 Million
Q3 2021

Nov 15, 2021
SELL
$205.93 - $447.23 $101,111 - $219,589
-491 Reduced 30.55%
1,116 $305,000
Q2 2021

Aug 16, 2021
BUY
$113.32 - $241.49 $182,105 - $388,074
1,607 New
1,607 $360,000

Others Institutions Holding BNTX

# of Institutions
356
Shares Held
38.3M
Call Options Held
2.45M
Put Options Held
2.29M
View Full List

About BioNTech SE

BNTX Quotes by TradingView
  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $26.3B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Capital International Sarl Portfolio

Follow Capital International Sarl and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Sarl, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Sarl with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email